应用流式细胞术评估多发性骨髓瘤预后的研究进展

Recent Advances on the Prognostic Value of Immunophenotyping in Multiple Myeloma by Flow Cytometry——Review

流式细胞术在多发性骨髓瘤方面的临床应用很为广泛,例如可以应用于与反应性浆细胞增多的区别诊断、疾病进展的监测、疾病预后的评估、微小残留病的监测等等。以流式细胞术为基础的免疫表型克隆分析,促进了更严格的诊断和随访技术的发展。本综述主要是介绍最新的骨髓瘤的恶性浆细胞的免疫表型、最广泛的抗原(如CD19,CD33,CD28,CD45,CD56及CD117)在正常的和恶性的浆细胞的表达的差别。本综述还着重介绍了恶性浆细胞表型和染色体异常之间的相关性,明确多发性骨髓瘤的预后因素。

Clinical application of flow cytometry in multiple myeloma （MM） can be found in various dimensions, such as in differential diagnosis of malignant plasma cell disorder from reactive plasmacytosis, identification of the progression risk in MM, and in the detection of minimal residual disease. Flow cytometry-based clonality assessment with immuno-phenotyping encourages and enables the most stringent method of diagnosis and follow-up. The objective of this review is to summarize the recent information of the malignant plasma cell phenotypic profile of MM. The most comprehensive antigens, such as CD19, CD27, CD28, CIM5, CD56 and CDll7, play a significant role in the characterization of normal and malignant plasma cells. This review also focuses on the association of malignant phenotypic markers with chromosomal aberrations that identify the specific prognostic factors in MM.